Rachel Narozniak, MA

Articles by Rachel Narozniak, MA

Gecacitinib Achieves Clinically Meaningful Spleen, Symptom, and Anemia Responses in JAK Inhibitor–Naive MF

Rachel Narozniak, MAMeeting News | June 1, 2025

Gecacitinib improved spleen volume, symptoms, and anemia in JAK inhibitor–naive MF, regardless of baseline anemia severity.

Five-Year SEQUOIA Data Show Zanubrutinib’s Durable Survival, Disease Control in High-Risk CLL/SLL

Rachel Narozniak, MAChronic Lymphocytic Leukemia | June 1, 2025

Zanubrutinib shows durable efficacy and safety in high-risk CLL/SLL, regardless of 17p deletion, per 5-year SEQUOIA data.

Second-line ASC Monotherapy Safely Elicits High Molecular Response Rates in Non-T315l-Mutant CML-CP

Rachel Narozniak, MAChronic Myeloid Leukemia | May 31, 2025

Asciminib shows safety and efficacy as a 2nd-line treatment in CML-CP without T315I, per interim phase 2 ASC2ESCALATE results